Process development and manufacturing will begin in the fourth quarter of 2017.
Japanese specialty pharmaceutical company Solasia Pharma, K.K. has selected contract development and manufacturing organization Alcami to provide the clinical supply of its active pharmaceutical ingredient (API) darinaparsin, a mitochondrial-targeted agent developed for the treatment of various hematologic and solid cancers.
Solasia Pharma, which is focused on the development of oncology drugs, in March 2011, acquired the rights to darinaparsin from ZIOPHARM Oncology, Inc. for the potential treatment of Peripheral T-Cell Lymphoma (PTCL). Presently darinaparsin is in Phase II trials in Asia.
Alcami is expected to begin proves development and clinical manufacturing of darinaparsin in the fourth quarter of 2017. The work will be completed at the company’s new highly potent API suites at its Center of Excellence facility in Germantown, WI.
Noted Mr. Yoshihiro Arai, president and chief executive officer of Solasia Pharma: "We are pleased to entrust Alcami with this project. Finding a responsible partner for the development and manufacturing of our API was a significant step in our clinical program."
Added Syed T. Husain, Chief Commercial Officer of Alcami: "We are extremely grateful for the opportunity to partner with Solasia as the trusted supplier of darinaparsin. Our relationship is an excellent example of Alcami's dedication to delivering reliable and high quality medicines across the globe. As we continue to grow our established business in Japan, we look forward to supporting Solasia for its future clinical and commercial success.”
